What question did this study set out to answer?

This study aims to evaluate the impact of HLA-B*5701 screening on the risk of hypersensitivity to abacavir.

February 6, 2008Open Access

HLA-B*5701 Screening for Hypersensitivity to Abacavir

Key Points

This study aims to evaluate the impact of HLA-B*5701 screening on the risk of hypersensitivity to abacavir.
HLA-B*5701 screening conducted in a predominantly white population
Pharmacogenetic testing applied to assess risk of hypersensitivity
ClinicalTrials.gov number, NCT00340080 provided for study registry.
94% of patients tested do not carry the HLA-B*5701 allele and are at low risk for abacavir hypersensitivity
Pharmacogenetic testing effectively prevents the toxic effect of abacavir

Abstract

HLA-B*5701 screening reduced the risk of hypersensitivity reaction to abacavir. In predominantly white populations, similar to the one in this study, 94% of patients do not carry the HLA-B*5701 allele and are at low risk for hypersensitivity reaction to abacavir. Our results show that a pharmacogenetic test can be used to prevent a specific toxic effect of a drug. (ClinicalTrials.gov number, NCT00340080.)

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Mallal et al. (Wed,) studied this question.

synapsesocial.com/papers/69de6b6f726bee048db0c06b https://doi.org/https://doi.org/10.1056/nejmoa0706135

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper